Concentra Group Holdings Reports Q4 Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2026
0mins
Should l Buy CON?
Source: seekingalpha
- Earnings Performance: Concentra Group Holdings reported a Q4 non-GAAP EPS of $0.28, aligning with market expectations, which indicates the company's stability in profitability despite competitive pressures in the market.
- Revenue Growth: The company reported Q4 revenue of $539.1 million, reflecting a year-over-year increase of 15.9%, showcasing strong demand in the healthcare sector and effective market strategies.
- Strategic Execution: Concentra is flawlessly executing its roll-up strategy, continuously expanding its market share and enhancing its competitiveness in the healthcare industry, which is expected to further drive revenue growth in the future.
- Future Outlook: The company released preliminary results for 2025 and provided guidance for 2026, demonstrating confidence in future growth while offering investors clear financial expectations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CON
Wall Street analysts forecast CON stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 22.440
Low
27.00
Averages
28.67
High
30.00
Current: 22.440
Low
27.00
Averages
28.67
High
30.00
About CON
Concentra Group Holdings Parent, Inc. is a provider of occupational health services in the United States. It delivers an extensive suite of services, including occupational and consumer health services and other direct-to-employer care, to more than 50,000 patients each day, on average, from about 620 occupational health centers in 41 states and 160 onsite health clinics at employer worksites in 36 states. Its Occupational Health Centers segment encompasses the services it delivers at its occupational health center facilities across the United States. Its Onsite Health Clinics segment delivers occupational health services and/or employer-sponsored primary care services at an employer’s workplace, including mobile health services and episodic specialty testing services. Its Other Businesses segment comprises several complementary services to its core occupational health services offering and includes Concentra Telemed, Concentra Pharmacy and Concentra Medical Compliance Administration.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Concentra Group Holdings Reports Strong Q4 2025 Earnings and 2026 Guidance
- Strong Financial Performance: Concentra reported Q4 2025 revenue of $539.1 million, a 15.9% year-over-year increase, with full-year revenue reaching $2.2 billion, up 13.9% from 2024, indicating robust market performance and sustained growth potential.
- Adjusted EBITDA Growth: The adjusted EBITDA for Q4 was $95.3 million, with a full-year adjusted EBITDA of $431.9 million, reflecting EBITDA margins of 17.7% and 20%, showcasing the company's success in cost management and operational efficiency.
- Clear Future Outlook: Management set 2026 revenue targets between $2.25 billion and $2.35 billion, with adjusted EBITDA targets of $450 million to $470 million, demonstrating confidence in future growth and clarity in strategic planning.
- Positive Market Feedback: CEO Newton highlighted that the average total workers' compensation claims cost for those treated by Concentra is 25% lower than non-Concentra providers, with claim durations reduced by 65 days, indicating competitive advantages and improved customer satisfaction.
See More
Concentra Group Holdings Declares Quarterly Dividend
- Quarterly Dividend Declaration: Concentra Group Holdings has declared a quarterly dividend of $0.0625 per share, maintaining the previous level, which indicates the company's stable cash flow and profitability.
- Yield Information: The forward yield of this dividend stands at 1.06%, reflecting the company's attractiveness in the current market environment, potentially appealing to income-seeking investors.
- Payment Schedule: The dividend will be payable on March 19, with a record date of March 12 and an ex-dividend date also on March 12, ensuring shareholders receive their dividends promptly, thereby boosting shareholder confidence.
- Dividend Growth Potential: By maintaining a consistent dividend policy, Concentra demonstrates its commitment to shareholder returns, which may attract more long-term investors and further enhance the company's market value.
See More
Concentra Group Holdings Reports Q4 Earnings Growth
- Earnings Performance Boost: Concentra Group's Q4 earnings reached $34.69 million, translating to $0.27 per share, which marks a significant increase from last year's $21.51 million and $0.17 per share, indicating enhanced profitability.
- Adjusted Earnings Growth: Excluding special items, Concentra reported adjusted earnings of $36.13 million, or $0.28 per share, showcasing the company's sustained growth potential in its core operations.
- Significant Revenue Increase: The company's Q4 revenue rose by 15.9% to $539.08 million, up from $465.04 million last year, reflecting strong market demand and the effectiveness of the company's sales strategies.
- Enhanced Market Competitiveness: With ongoing earnings and revenue growth, Concentra solidifies its market position within the industry, positioning itself for potential market share expansion and increased investor confidence in the future.
See More
Concentra Group Holdings Reports Q4 Highlights
- Earnings Performance: Concentra Group Holdings reported a Q4 non-GAAP EPS of $0.28, aligning with market expectations, which indicates the company's stability in profitability despite competitive pressures in the market.
- Revenue Growth: The company reported Q4 revenue of $539.1 million, reflecting a year-over-year increase of 15.9%, showcasing strong demand in the healthcare sector and effective market strategies.
- Strategic Execution: Concentra is flawlessly executing its roll-up strategy, continuously expanding its market share and enhancing its competitiveness in the healthcare industry, which is expected to further drive revenue growth in the future.
- Future Outlook: The company released preliminary results for 2025 and provided guidance for 2026, demonstrating confidence in future growth while offering investors clear financial expectations.
See More
Concentra Reports Strong 2025 Financial Results
- Significant Revenue Growth: Concentra reported fourth-quarter revenue of $539.08 million for 2025, reflecting a 15.9% increase year-over-year, indicating strong demand in the occupational health services sector and reinforcing its market leadership.
- Substantial Net Income Increase: The company achieved a net income of $36.19 million in the fourth quarter of 2025, up 58.7% from the previous year, showcasing effective cost control and operational efficiency improvements that bolster investor confidence.
- Improved Free Cash Flow: Free cash flow for the fourth quarter of 2025 reached $98.56 million, a 28% increase from $77.03 million in the same quarter last year, demonstrating the company's ongoing enhancement in cash generation capabilities, which supports future investments and shareholder returns.
- Dividend Declaration: On February 25, 2026, the Board of Directors declared a cash dividend of $0.0625 per share, payable on or about March 19, 2026, reflecting the company's confidence in its financial health, although future dividends will still require careful consideration by the Board.
See More
Concentra Releases Preliminary Financial Results for FY 2025
- Significant Revenue Growth: For FY 2025, Concentra expects revenue to reach $2.1634 billion, a 13.9% increase from $1.9002 billion in FY 2024, indicating strong market demand and business expansion capabilities in the occupational health services sector.
- Substantial Net Income Increase: The anticipated net income for FY 2025 is $172.8 million, slightly up from $171.9 million in FY 2024, reflecting ongoing improvements in cost control and operational efficiency.
- Record Patient Visits: In FY 2025, patient visits are projected to total 13,546,707, averaging 53,124 visits per day, which is a 7.7% increase from 49,311 visits per day in FY 2024, demonstrating success in enhancing customer service and market penetration.
- Optimistic 2026 Outlook: Concentra forecasts revenue for 2026 to be between $2.25 billion and $2.35 billion, with adjusted EBITDA expected to be between $450 million and $470 million, showcasing confidence in future growth and effective strategic planning.
See More
Concentra Group Holdings Reports Strong Q4 2025 Earnings and 2026 Guidance
- Strong Financial Performance: Concentra reported Q4 2025 revenue of $539.1 million, a 15.9% year-over-year increase, with full-year revenue reaching $2.2 billion, up 13.9% from 2024, indicating robust market performance and sustained growth potential.
- Adjusted EBITDA Growth: The adjusted EBITDA for Q4 was $95.3 million, with a full-year adjusted EBITDA of $431.9 million, reflecting EBITDA margins of 17.7% and 20%, showcasing the company's success in cost management and operational efficiency.
- Clear Future Outlook: Management set 2026 revenue targets between $2.25 billion and $2.35 billion, with adjusted EBITDA targets of $450 million to $470 million, demonstrating confidence in future growth and clarity in strategic planning.
- Positive Market Feedback: CEO Newton highlighted that the average total workers' compensation claims cost for those treated by Concentra is 25% lower than non-Concentra providers, with claim durations reduced by 65 days, indicating competitive advantages and improved customer satisfaction.
See More
Concentra Group Holdings Declares Quarterly Dividend
- Quarterly Dividend Declaration: Concentra Group Holdings has declared a quarterly dividend of $0.0625 per share, maintaining the previous level, which indicates the company's stable cash flow and profitability.
- Yield Information: The forward yield of this dividend stands at 1.06%, reflecting the company's attractiveness in the current market environment, potentially appealing to income-seeking investors.
- Payment Schedule: The dividend will be payable on March 19, with a record date of March 12 and an ex-dividend date also on March 12, ensuring shareholders receive their dividends promptly, thereby boosting shareholder confidence.
- Dividend Growth Potential: By maintaining a consistent dividend policy, Concentra demonstrates its commitment to shareholder returns, which may attract more long-term investors and further enhance the company's market value.
See More
Concentra Group Holdings Reports Q4 Earnings Growth
- Earnings Performance Boost: Concentra Group's Q4 earnings reached $34.69 million, translating to $0.27 per share, which marks a significant increase from last year's $21.51 million and $0.17 per share, indicating enhanced profitability.
- Adjusted Earnings Growth: Excluding special items, Concentra reported adjusted earnings of $36.13 million, or $0.28 per share, showcasing the company's sustained growth potential in its core operations.
- Significant Revenue Increase: The company's Q4 revenue rose by 15.9% to $539.08 million, up from $465.04 million last year, reflecting strong market demand and the effectiveness of the company's sales strategies.
- Enhanced Market Competitiveness: With ongoing earnings and revenue growth, Concentra solidifies its market position within the industry, positioning itself for potential market share expansion and increased investor confidence in the future.
See More
Concentra Group Holdings Reports Q4 Highlights
- Earnings Performance: Concentra Group Holdings reported a Q4 non-GAAP EPS of $0.28, aligning with market expectations, which indicates the company's stability in profitability despite competitive pressures in the market.
- Revenue Growth: The company reported Q4 revenue of $539.1 million, reflecting a year-over-year increase of 15.9%, showcasing strong demand in the healthcare sector and effective market strategies.
- Strategic Execution: Concentra is flawlessly executing its roll-up strategy, continuously expanding its market share and enhancing its competitiveness in the healthcare industry, which is expected to further drive revenue growth in the future.
- Future Outlook: The company released preliminary results for 2025 and provided guidance for 2026, demonstrating confidence in future growth while offering investors clear financial expectations.
See More
Concentra Reports Strong 2025 Financial Results
- Significant Revenue Growth: Concentra reported fourth-quarter revenue of $539.08 million for 2025, reflecting a 15.9% increase year-over-year, indicating strong demand in the occupational health services sector and reinforcing its market leadership.
- Substantial Net Income Increase: The company achieved a net income of $36.19 million in the fourth quarter of 2025, up 58.7% from the previous year, showcasing effective cost control and operational efficiency improvements that bolster investor confidence.
- Improved Free Cash Flow: Free cash flow for the fourth quarter of 2025 reached $98.56 million, a 28% increase from $77.03 million in the same quarter last year, demonstrating the company's ongoing enhancement in cash generation capabilities, which supports future investments and shareholder returns.
- Dividend Declaration: On February 25, 2026, the Board of Directors declared a cash dividend of $0.0625 per share, payable on or about March 19, 2026, reflecting the company's confidence in its financial health, although future dividends will still require careful consideration by the Board.
See More
Concentra Releases Preliminary Financial Results for FY 2025
- Significant Revenue Growth: For FY 2025, Concentra expects revenue to reach $2.1634 billion, a 13.9% increase from $1.9002 billion in FY 2024, indicating strong market demand and business expansion capabilities in the occupational health services sector.
- Substantial Net Income Increase: The anticipated net income for FY 2025 is $172.8 million, slightly up from $171.9 million in FY 2024, reflecting ongoing improvements in cost control and operational efficiency.
- Record Patient Visits: In FY 2025, patient visits are projected to total 13,546,707, averaging 53,124 visits per day, which is a 7.7% increase from 49,311 visits per day in FY 2024, demonstrating success in enhancing customer service and market penetration.
- Optimistic 2026 Outlook: Concentra forecasts revenue for 2026 to be between $2.25 billion and $2.35 billion, with adjusted EBITDA expected to be between $450 million and $470 million, showcasing confidence in future growth and effective strategic planning.
See More
